Daihan Pharmaceutical financials at a glance

+ Portfolio

The revenue of Daihan Pharmaceutical is reported as 184.26755 billion Won in the fiscal year 2023. The earnings were 4171 Won per share in 2023, which was 10.4 higher than 2021. And about 18.5296 billion Won are reported as free cash flow in the financials of Daihan Pharmaceutical 2023. Dividends of 650 Won per share were paid to shareholders of Daihan Pharmaceutical stock KOSDAQ:A023910 in fiscal 2023.

₩184.27B

Revenue

₩4.17k

Earnings Per Share

32.46%

Gross Margin %

₩0.00M

Free Cash Flow

Revenue

184,267.55

Earnings Per Share

4,171.00

Gross Margin %

32.46

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019	2018	2017	2016	2014	2013
Rev.	Revenue	N/A	₩184.27B	₩171.46B	₩166.08B	₩168.76B	₩158.72B	₩144.44B	₩139.44B	₩111.71B	₩0.00M
GM %	Gross Margin %	33.09%	32.46%	32.47%	33.84%	35.08%	37.76%	37.74%	31.00%	30.35%	28.13%
OM	Operating Margin	18.23%	17.89%	16.95%	18.04%	19.93%	22.82%	22.33%	15.58%	12.48%	11.78%
EPS	Earnings Per Share	₩4.45k	₩4.17k	₩3.78k	₩2.90k	₩4.69k	₩4.75k	₩4.14k	₩2.94k	₩1.36k	₩1.30k
Div.	Dividends	N/A	₩650.00	₩400.00	₩0.00	₩400.00	₩300.00	₩300.00	₩220.00	₩120.00	₩0.00
PR %	Payout Ratio %	0	15.58%	10.59%	0	8.52%	6.31%	7.25%	7.48%	8.86%	0
Sha.	Shares	N/AM	5.88M	6M	6M	6M	6M	6M	6M	6M	6M
OCF	Operating Cash Flow	N/A	₩29.00B	₩40.62B	₩0.00M	₩35.26B	₩44.94B	₩20.45B	₩27.92B	₩9.48B	₩0.00M
FCF	Free Cash Flow	N/A	₩20.38B	₩28.77B	₩0.00M	₩17.96B	₩-1,747.75M	₩-,592.25M	₩6.03B	₩-,986.42M	₩0.00M
FCFS	Free Cash Flow Per Share	₩4.10k	₩3.41k	₩4.79k	₩4.71k	₩2.99k	₩-,291.29	₩-98.71	₩1.00k	₩-,165.57	₩-1,090.39

Daihan Pharmaceutical financials at a glance

Financials

Discover